Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 501–600 of 1,000
Almirall, D., Nahum-Shani, I. B., Wang, L., & Kasari, C. L. (2018) · Statistics for social and behavioral sciences · doi:10.1007/978-3-319-91776-4_4 · Cited by 51
Malone, R. P., Gratz, S. S., Delaney, M. A., & Hyman, S. L. (2005) · CNS Drugs · doi:10.2165/00023210-200519110-00003 · Cited by 45
Care of the patient with an autism spectrum disorder by the general physician
Venkat, A., Jauch, E., Russell, W. S., Crist, C. R., & Farrell, R. (2012) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2011-130727 · Cited by 41
Roke, Y., van Harten, P. N., Buitelaar, J. K., Tenback, D. E., Quekel, L. G. B. A., de Rijke, Y. B., & Boot, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0521 · Cited by 42
Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update
Pillay, J., Boylan, K., Newton, A. S., Hartling, L., Vandermeer, B., Nuspl, M., MacGregor, T., Featherstone, R. M., & CARREY, N. J. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718779950 · Cited by 48
Mikita, N., & Stringaris, A. (2013) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0355-9 · Cited by 43
“For example, it is unclear whether atypical antipsychotics, such as risperidone, used in the treatment of irritability in autism [31], would be a viable treatment option for irritability in typically developing youth with SMD.”
BackgroundAripiprazole in Children and Adolescents: Clinical Experience
Rugino, T. A., & Janvier, Y. M. (2005) · Journal of Child Neurology · doi:10.1177/08830738050200071301 · Cited by 46
“pain or emesis; (3) a known adverse reaction to any antipsychotic medication”
BackgroundAsperger's Syndrome and High-Functioning Autism
Carpenter, L. A., Soorya, L. V., & Halpern, D. B. (2009) · Pediatric Annals · doi:10.3928/00904481-20090101-01 · Cited by 57
Dieleman, L. M., Pauw, S. S. W. D., Soenens, B., Beyers, W., & Prinzie, P. (2016) · Development and Psychopathology · doi:10.1017/s0954579416001243 · Cited by 58
“Specifically, we examined the role of age, gender, autism severity, level of maternal education, and type of medication as each of these characteristics have been suggested to affect parenting or child behavior in youth with ASD (Holtmann et al., 2007; McCracken et al., 2002; Smith et al., 2008).”
Backgroundde León, J., Sandson, N. B., & Cozza, K. L. (2008) · Psychosomatics · doi:10.1176/appi.psy.49.4.347 · Cited by 47
Mehler‐Wex, C., Kölch, M. G., Kirchheiner, J., Antony, G., Fegert, J. M., & Gerlach, M. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-14 · Cited by 51
“Most data about second generation antipsychotics in minors were collected by Research Units on Pediatric Psychopharmacology, driven by the "pediatric rule" [18].”
Veenstra-VanderWeele, J. M., Jessen, T. N., Thompson, B. J., Carter, M. D., Prasad, H. C., Steiner, J. A., Sutcliffe, J. S., & Blakely, R. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9020-0 · Cited by 45
“More consistent data supports the use of risperidone [44, 45], an atypical antipsychotic with antagonism at multiple monoamine receptors, including the 5-HT2A receptor.”
BackgroundCarlson, G. A., Potegal, M., Margulies, D., Basile, J., & Gutkovich, Z. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00793.x · Cited by 42
Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism
Silverman, J. L., Babineau, B. A., Oliver, C. F., Karras, M. N., & Crawley, J. N. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.042 · Cited by 42
Neurological considerations: Autism and Parkinson's disease
Hollander, E., Wang, A. T., Braun, A. R., & Marsh, L. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.07.014 · Cited by 47
“Clearly, dopaminergic dysfunction may also play a prominent role both in OCD (Hollander et al., 2003b) and autism (McCracken et al., 2002), since both conditions have a favorable response to atypical antipsychotic agents such as risperidone.”
Handen, B. L., Melmed, R. D., Hansen, R. L., Aman, M. G., Burnham, D. L., Bruss, J. B., & McDougle, C. J. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0687-y · Cited by 43
Self-citationRagnauth, A. K., Goodwillie, A., Brewer, C., Muglia, L. J., Pfaff, D. W., & Kow, L.-M. (2004) · Neuroendocrinology · doi:10.1159/000081844 · Cited by 41
Neurological Adverse Effects of Antipsychotics in Children and Adolescents
García-Amador, M., Merchán‐Naranjo, J., Tapia, C., Moreno, C., Castro‐Fornieles, J., Baeza, I., de la Serna, E., Alda, J. A., Muñoz, D., Nestares, P. A., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000419 · Cited by 42
“The few short-term placebo-controlled trials are limited to schizophrenia,(7,8) bipolar disorder,(9) or behavioral problems associated with autism, low IQ, or attention-deficit/hyperactivity disorder.(10) Neuromotor(7,10,11) and cognitive adverse effects(7,12) have been detected in pediatric patients treated with SGAs.”
BackgroundAntipsychotics use in children and adolescents: An on-going challenge in clinical practice
Schneider, C., Taylor, D. M., Zalsman, G., Frangou, S., & Kyriakopoulos, M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114533599 · Cited by 41
Autismo: tratamentos psicofarmacológicos e áreas de interesse para desenvolvimentos futuros
Nikolov, R., Jonker, J., & Scahill, L. D. (2006) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006000500006 · Cited by 128
Self-citationSukhodolsky, D. G., Wyk, B. C. V., Eilbott, J. A., McCauley, S. A., Ibrahim, K., Crowley, M. J., & Pelphrey, K. A. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0164 · Cited by 46
Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder
Thom, R. P., Keary, C. J., Palumbo, M. L., Ravichandran, C. T., Mullett, J. E., Hazen, E. P., Neumeyer, A. M., & McDougle, C. J. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05280-6 · Cited by 46
Self-citationSchnapp, A., Harel, M., Cayam-Rand, D., Cassuto, H., Polyansky, L., & Aran, A. A. (2022) · Biomedicines · doi:10.3390/biomedicines10071685 · Cited by 56
“Clinical Global Impression–Improvement scale (CGI-I) [40] was used to measure the improvement in disruptive behaviors from the baseline.”
BackgroundMethodInfluentialPringsheim, T., & Gorman, D. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205701203 · Cited by 41
Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autism Spectrum Disorder
Wong, V. C., & Sun, J.-G. (2010) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2007.0768 · Cited by 41
“As we are the first researchers in performing pilot studies of the efficacy of acupuncture in chronic neurological diseases in children (e.g., cerebral palsy, drooling, autism) using randomized controlled trials, 49–54 we hope that our selection of acupoints both for the tongue or body (Fig.”
Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats
Choi, Y. K., Moran‐Gates, T., Gardner, M., & Tarazi, F. I. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.09.002 · Cited by 41
Aberrant Behavior Checklist: Current Identity and Future Developments
Aman, M. G. (2012) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000e114 · Cited by 50
Self-citationManaging attention deficit/hyperactivity disorder: unmet needs and future directions
Steer, C. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.059352 · Cited by 46
Vitiello, B., Heiligenstein, J. H., Riddle, M. A., Greenhill, L. L., & Fegert, J. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.011 · Cited by 42
Self-citationIntestinal nematode infection and anaemia in developing countries
Awasthi, S., & Bundy, D. A. P. (2007) · BMJ · doi:10.1136/bmj.39211.572905.80 · Cited by 42
Neurochemical evidence for differential effects of acute and repeated oxytocin administration
Benner, S., Aoki, Y., Watanabe, T., Endo, N., Abe, O., Kuroda, M., Kuwabara, H., Kawakubo, Y., Takao, H., Kunimatsu, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0249-4 · Cited by 40
Intramuscular Ziprasidone for Acute Agitation in Adolescents
Hazaray, E., Ehret, J., Posey, D. J., Petti, T. A., & McDougle, C. J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546042389055 · Cited by 43
Self-citationJavaheri, K. R., & McLennan, J. D. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0167 · Cited by 41
Psychotropic Polypharmacy Among Children and Youth with Autism: A Systematic Review
Ritter, C., Hewitt, K., & McMorris, C. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0110 · Cited by 45
“…FDA-approved medications for autism (risperidone and aripiprazole) seem to only display moderate effectiveness and have been associated with substantial side effects such as sedation, obesity, dizziness, drooling, and tardive dyskinesia (McCracken et al. 2002; Warren et al. 2011; Dove et al. 2012).”
Roke, Y., van Harten, P. N., Franke, B., Galesloot, T. E., Boot, A. M., & Buitelaar, J. K. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283647c33 · Cited by 43
New Experimental Treatments for Core Social Domain in Autism Spectrum Disorders
Canitano, R. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00061 · Cited by 46
Aripiprazole for treating irritability associated with autism spectrum disorders
Bartram, L. R., Lozano, J., & Coury, D. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1626825 · Cited by 47
“Irritability is a common symptom in children and adolescents with ASD and can affect participation and functioning in school, home, and other environments [3].”
BackgroundPsychotropic medicine prescriptions in Italian youths: a multiregional study
Piovani, D., Clavenna, A., Cartabia, M., & Bonati, M. R. (2015) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-015-0726-0 · Cited by 46
“Large randomised clinical trials focused on the treatment of a spectrum of psychiatric illnesses—such as hyperactivity disorder (ADHD) [1], bipolar mania [2], behavioural problems associated with autism [3], and depressive [4] and anxiety disorders [5]— have been published, and the emphasis on pharmacological treatmen…”
BackgroundMachado, R. F. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1826 · Cited by 40
Addressing sleep disorder of autistic children with Qur’anic sound therapy
Tumiran, M. A., Mohamad, S. P., Saat, R. M., Yusoff, Z. M., Rahman, N. N. A., & Adli, D. S. H. (2013) · Health · doi:10.4236/health.2013.58a2011 · Cited by 46
Ehrenreich-May, J., Storch, E. A., Queen, A. H., Hernandez Rodriguez, J., Ghilain, C. S., Alessandri, M., Lewin, A. B., Arnold, E. B., Murphy, T. K., Lin, C. E., et al. (2014) · Focus on Autism and Other Developmental Disabilities · doi:10.1177/1088357614533381 · Cited by 40
Tuchman, R. F. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(03)00011-2 · Cited by 54
Psychiatry: Role of Risperidone in Children with Autism Spectrum Disorder
Chavez, B., Chavez-Brown, M., & Rey, J. A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g389 · Cited by 39
Scahill, L., McCracken, J., McDougle, C. J., Aman, M., Arnold, L. E., Tierney, E., Cronin, P., Davies, M., Ghuman, J., Gonzalez, N., et al. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601317261555 · Cited by 42
Self-citationStorch, E. A., Arnold, E. B., Jones, A. M., Ale, C. M., Wood, J. J., Ehrenreich, J. T., Lewin, A. B., Mutch, P. J., & Murphy, T. K. (2012) · Child Psychiatry & Human Development · doi:10.1007/s10578-012-0294-1 · Cited by 44
Wink, L. K., Reisinger, D. L., Horn, P. S., Shaffer, R. C., O’Brien, K., Schmitt, L., Dominick, K. C., Pedapati, E. V., & Erickson, C. A. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04542-z · Cited by 43
Placebo effect in child and adolescent psychiatric trials
Parellada, M., Moreno, C., Moreno, M., Espliego, A., Portugal, E., & Arango, C. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.007 · Cited by 41
“In clinical conditions such as irritability in autism (Munarriz et al., 2002) or hyperactive symptoms in ADHD (Peterson et al.”
Aman, M. G., Vinks, A. A. T. M. M., Remmerie, B. M. M., Mannaert, E., Ramadan, Y., Masty, J. K., Lindsay, R. L., & Malone, K. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.026 · Cited by 51
Self-citationManeeton, N., Maneeton, B., Putthisri, S., Suttajit, S., Likhitsathian, S., & Srisurapanont, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s174622 · Cited by 41
“Similarly to risperidone, the tolerability of aripiprazole as measured in the discontinuation rate due to adverse events was not different from placebo in such treatment.(8,11,35) In addition to its efficacy, aripiprazole may be considered in the treatment of ASD in children and adolescents since it has more acceptabi…”
BackgroundWang, J., Zhou, X. P., Xia, W. T., Sun, C., Wu, L., Wang, J., & Tomoda, A. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-7 · Cited by 44
Risperidone and liver function tests in children and adolescents: A short-term prospective study
Erdoğan, A., Atasoy, N., Akkurt, H., Ozturk, D., Karaahmet, E., Yaluğ, İ., Yaluğ, K., Ankaralı, H. Ç., & Balcıoğlu, İ. C. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.12.032 · Cited by 39
Safety issues with drug therapies for autism spectrum disorders.
McCracken, J. T. (2005) · PubMed · Cited by 47
Self-citationThe Pathophysiology, Medical Management, and Dental Implications of Autism
Friedlander, A. H., Yagiela, J. A., Paterno, V. I., & Mahler, M. E. (2003) · Journal of the California Dental Association · doi:10.1080/19424396.2003.12224215 · Cited by 38
Hellings, J. A., Zarcone, J. R., Valdovinos, M. G., Reese, R. M., Gaughan, E. T., & Schroeder, S. R. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.885 · Cited by 39
Psychopharmacology of Autistic Spectrum Disorders in Children and Adolescents
Nazeer, A. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.011 · Cited by 40
Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms
Singh, R. S., Turner, R. C., Nguyen, L., Motwani, K., Swatek, M., & Lucke-Wold, B. P. (2016) · Behavioural Neurology · doi:10.1155/2016/8781725 · Cited by 44
Scalp acupuncture treatment for children's autism spectrum disorders
Liu, C., Li, T., Wang, Z., Zhou, R., & Zhuang, L. (2019) · Medicine · doi:10.1097/md.0000000000014880 · Cited by 37
Hall, S. S., Monlux, K. D., Rodriguez, A. B., Jo, B., & Pollard, J. S. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09331-4 · Cited by 39
“Although behavioral treatment research is limited for children with FXS [13, 30], several studies have shown that FCT interventions for problem behaviors can be successfully implemented via telehealth for young children with ASD [53, 54].”
ResultInfluentialLeBlanc, J. C., Binder, C. E., Armenteros, J. L., Aman, M. G., Wang, J. S., Hew, H., & Kusumakar, V. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000166403.03732.72 · Cited by 42
“In other studies, treatment with risperidone has also been associated with marked reductions in aggression among children with autistic spectrum disorder (McDougle et al., 2001; Research Units on Pediatric Psychopharmacology Autism Network, 2002).”
ResultSelf-citationScahill, L. D., Koenig, K. M., Carroll, D. H., & Pachler, M. C. (2007) · Journal of Child and Adolescent Psychiatric Nursing · doi:10.1111/j.1744-6171.2007.00112.x · Cited by 41
Self-citationMedical Therapies for Children With Autism Spectrum Disorder—An Update
Edwin Williamson, M. D., Sathe, N. A., & Andrews, J. C. (2017) · doi:10.23970/ahrqepccer189 · Cited by 47
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders
Wink, L. K., Plawecki, M. H., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.487860 · Cited by 36
Self-citationLamy, M., Pedapati, E. V., Dominick, K. C., Wink, L. K., & Erickson, C. A. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00408-0 · Cited by 43
Popow, C., Ohmann, S., & Plener, P. L. (2021) · Neuropsychiatrie · doi:10.1007/s40211-021-00395-9 · Cited by 36
Huang, M., Shentu, J., Chen, J., Liu, J., & Zhou, H. (2008) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0710439 · Cited by 36
“It is effective in the treatment of schizophrenia and other psychiatric illnesses in adults and children including pervasive developmental disorders, autism and attention-deficit disorder (McCracken et al., 2002; McDougle et al., 2005).”
BackgroundMemari, A. H., Ziaee, V., Beygi, S., Moshayedi, P., & Mirfazeli, F. S. (2011) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2011.10.001 · Cited by 41
Promoting social attention in 3‐year‐olds with ASD through gaze‐contingent eye tracking
Wang, Q., Wall, C. A., Barney, E. C., Bradshaw, J. L., Macari, S. L., Chawarska, K., & Shic, F. (2019) · Autism Research · doi:10.1002/aur.2199 · Cited by 44
“Refinement of GCET training systems may consider the nature of specific attentional deficits to achieve optimal efficacy, much like traditional interventions where minimum symptom thresholds are often criteria for inclusion [Hardan et al., 2014; McCracken et al., 2002; Owen et al., 2009].”
BackgroundPharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents
Masi, G. (2004) · CNS Drugs · doi:10.2165/00023210-200418140-00006 · Cited by 35
Research Knowledge Among Parents of Children Participating in a Randomized Clinical Trial
Vitiello, B., Aman, M. G., Scahill, L. D., McCracken, J. T., McDougle, C. J., Tierney, E., Davies, M., & Arnold, L. E. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200502000-00006 · Cited by 35
Self-citationCutoff scores for the Autism Spectrum Disorder – Comorbid for Children (ASD-CC)
Thorson, R. T., & Matson, J. L. (2011) · Research in Autism · doi:10.1016/j.rasd.2011.07.016 · Cited by 37
Cobaugh, D. J., Erdman, A. R., Booze, L. L., Scharman, E. J., Christianson, G., Manoguerra, A. S., Caravati, E. M., Chyka, P. A., Woolf, A. D., Nelson, L. S., et al. (2007) · Clinical Toxicology · doi:10.1080/15563650701665142 · Cited by 35
Comprehensive Management of Autism: Current Evidence
Shenoy, M. D., Indla, V., & Reddy, H. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_272_17 · Cited by 41
“It is considered first line of medication for children and adolescents who display extreme irritability.([14])”
BackgroundA systematic review of cannabidiol trials in neurodevelopmental disorders
Parrella, N.-F., Hill, A. T., Enticott, P. G., Barhoun, P., Bower, I. S., & Ford, T. C. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173607 · Cited by 43
Review of the pharmacotherapy of irritability of autism.
Elbe, D., & Lalani, Z. (2012) · PubMed · Cited by 45
Frankel, F., Myatt, R., & Feinberg, D. T. (2007) · Child Psychiatry & Human Development · doi:10.1007/s10578-007-0053-x · Cited by 39
Subject Selection and Characterization in Clinical Trials in Children with Autism
Scahill, L. D., & Lord, C. (2004) · CNS Spectrums · doi:10.1017/s1092852900008336 · Cited by 34
Self-citationProblem behaviours and Major Depressive Disorder in adults with intellectual disability and autism
Baudewijns, L., Ronsse, E., Verstraete, V., Sabbe, B., Morrens, M., & Bertelli, M. O. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.039 · Cited by 36
Multidisciplinary treatment plan for challenging behaviors in neurodevelopmental disorders
Guinchat, V., Cravero, C., Lefèvre-Utile, J., & Cohen, D. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64148-9.00022-3 · Cited by 37
Brandenburg, C., Soghomonian, J., Zhang, K., Sulkaj, I., Randolph, B., Kachadoorian, M., & Blatt, G. J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577858 · Cited by 40
Schwartzman, J. M., Hardan, A. Y., & Gengoux, G. W. (2021) · Autism · doi:10.1177/1362361321998560 · Cited by 35
“…on a 7-point Likert-type scale with ratings ranging from “1—normal” to “4—moderately ill” to “7—extremely ill.” The CGI has been used in several clinical trials in ASD and found to be a reliable estimate of severity of symptoms (Bearss et al., 2015; King et al., 2009; McCracken et al., 2002).”
MethodOu, J., Smith, R. C., Tobe, R. H., Lin, J., Arriaza, J., Fahey, J. W., Liu, R., Zeng, Y., Liu, Y., Huang, L., et al. (2022) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-022-05784-9 · Cited by 38
“Although the CGI-S scale has not been validated as an autism-specific scale, it is frequently used to measure outcomes in autism-focused clinical trials (Hollander et al., 2022; McCracken et al., 2002).”
Atypical Antipsychotics in Children with Pervasive Developmental Disorders
Chavez, B., Chávez-Brown, M., Sopko, M. A., & Rey, J. A. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709040-00006 · Cited by 36
Moving From Research to Practice in the Primary Care of Children With Autism Spectrum Disorders
Carbone, P. S. (2013) · Academic Pediatrics · doi:10.1016/j.acap.2013.04.003 · Cited by 37
Troost, P. W., Althaus, M., Lahuis, B. E., Buitelaar, J. K., Minderaa, R. B., & Hoekstra, P. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.561 · Cited by 33
Doyle, R. L., Frazier, J., Spencer, T. J., Geller, D., Biederman, J., & Wilens, T. (2006) · Journal of Attention Disorders · doi:10.1177/1087054705284091 · Cited by 33
“Neuroleptics have been used for behavioral dyscontrol and mood stabilization in individuals with PDD (McCracken et al., 2002).”
Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder
Carminati, G. G., Gerber, F., Darbellay, B., Kosel, M., Deriaz, N., Chabert, J., Fathi, M., Bertschy, G., Ferrero, F., & Carminati, F. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.09.002 · Cited by 34
Paliperidone Palmitate in a Child with Autistic Disorder
Kowalski, J. L., Wink, L. K., Blankenship, K. M., Habenicht, C. D., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0035 · Cited by 32
Self-citationNew directions in the treatment of autism spectrum disorders from animal model research
Chadman, K. K., Guariglia, S. R., & Yoo, J. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.678828 · Cited by 35
“appetite with associated weight gain and sedation [18].”
BackgroundChange in Plasma Cytokine Levels During Risperidone Treatment in Children with Autism
Choi, J. E., Widjaja, F., Careaga, M., Bent, S., Ashwood, P., & Hendren, R. L. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0108 · Cited by 31
“Using the same parameters as McCracken et al. (2002), subjects were defined as overall responders to treatment if they had a decrease in ABC-I ‡ 25% and a Clinical Global Impressions-Improvement (CGI-I) rating of ‘‘very much improved’’ or ‘‘much PLASMA CYTOKINE LEVELS DURING RISPERIDONE TREATMENT…”
Paliperidone for Irritability in Autistic Disorder
Stigler, K. A., Erickson, C. A., Mullett, J. E., Posey, D. J., & McDougle, C. J. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0019 · Cited by 32
Self-citationRisperidone in the management of agitation and aggression associated with psychiatric disorders
Deyn, P. P. D., & Buitelaar, J. K. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.11.003 · Cited by 34
“Mean weight gain higher with risperidone than placebo McCracken et al. 2002 [35] Risperidone (1.2 mg; 40) Placebo (39) 8 weeks PDD (7.5) Mean ABC irritability score decreased 64% with risperidone vs. 31% with placebo (P ≤ 0.”
BackgroundInfluentialPsychiatric disorders in children with Prader–Willi syndrome—Results of a 2‐year longitudinal study
Lo, S., Collin, P. J. L., & Hokken‐Koelega, A. C. S. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36998 · Cited by 34
“Antipsychotics such as Risperidone and Aripiprazole have been described to be effective in reducing irritability in children and adolescents with autism [McCracken et al., 2002; Owen et al., 2009].”
BackgroundAsperger syndrome and high functioning autism: research concerns and emerging foci
Blacher, J., Kraemer, B., & Schalow, M. (2003) · Current Opinion in Psychiatry · doi:10.1097/00001504-200309000-00008 · Cited by 37
Effects of risperidone on dopamine receptor subtypes in developing rat brain
Moran‐Gates, T., Grady, C. J., Park, Y. S., Baldessarini, R. J., & Tarazi, F. I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.10.004 · Cited by 32
“…autism, Asperger’s syndrome, childhood disintegrative disorder, and Rett syndrome, RSP was effective in ameliorating the core symptoms, including hyperactivity, unstable mood, aggression and self-injurious behaviors (Perry et al. 1997;Barnard et al. 2002;McCracken et al. 2002;Erickson et al. 2005).”
BackgroundAEDs and psychotropic drugs in children with autism and epilepsy
Tuchman, R. F. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20026 · Cited by 33
Moreira, M. D. S., & Aragão, G. F. (2022) · Amplla Editora eBooks · doi:10.51859/amplla.tea2232-1 · Cited by 31
Deb, S. S., Roy, M., Limbu, B., Brizard, B. A., M.Murugan, M. P. A., Roy, A., & Santambrogio, J. (2023) · Psychological Medicine · doi:10.1017/s003329172300212x · Cited by 34
Maeda, H. A., Chiyonobu, T., Yoshida, M., Yamashita, S., Zuiki, M., Kidowaki, S., Isoda, K., Yamakawa, K., Morimoto, M., Nakahata, T., et al. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.5 · Cited by 31
Holdman, R., Vigil, D., Robinson, K. J., Shah, P., & Contreras, A. E. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0154 · Cited by 39
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Henneberry, E. A., Lamy, M., Dominick, K. C., & Erickson, C. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05237-9 · Cited by 32
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.